The best of STAT+ 🏅 May subscriber benefits

Enjoy discounts on STAT Reports and events, free access to data tools like our CRISPR TRACKR, and daily coverage of the life sciences. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

www.statnews.com/stat-plus Subscribe to STAT+ and access exclusive benefits this month When you're a STAT+ subscriber, you get to enjoy perks like discounts on our STAT Reports and events, free access to premium data tools like our CRISPR TRACKR, as well as in-depth daily coverage and analysis of the life sciences. SUBSCRIBE Our Latest STAT Report on Clinical Trial Delays When it comes to clinical trials, time is money. And a delay in a trial can mean a drop in a drug's net value, lost ground to competitors, or an increased risk of failure — or it can signal more bad news to come. But not all trial delays are red flags. In this special STAT Report, the first of three on clinical trials, biopharma consultant Frank David, M.D., Ph.D., provides the answers that people who track the progress of clinical trials need most. Purchase the report now for $149 and access valuable insights on clinical trial delays and how to predict the difference between minor inconveniences and major red flags. You will also receive one month of access to STAT Trials Pulse, AppliedXL's AI-powered platform that automates clinical trials intelligence, saving you time and surfacing early risk indicators. STAT+ subscribers can get a 20% discount on all STAT Reports. Purchase STAT@ASCO: Science vs. Cancer Date: June 4, 2023 at 5:00pm CT Location: Convene - Willis Tower, Chicago, IL The annual ASCO meeting is one of the leading showcases for new science about cancer treatment. STAT will take a deep look at the latest data on how to outsmart tumors and break down the big issues facing developers of new oncology medicines.  STAT+ subscribers can attend in person for free or receive a 40% discount on a virtual pass. Sign Up STAT SUMMIT Future Summit Date: September 5 - 7, 2023 Location: Virtual This virtual summit will bring together big name executives, global policymakers and patient advocates for deep discussions on the state of healthcare and the future of research and development.  STAT + Subscribers can attend for free!  LEARN MORE Challenges for today's transformative gene and cell therapies Gene editing and cell therapy have revolutionized medicine and given patients with serious or life-threatening illnesses an increased chance for remission. But access, varying regulations, and cost and risk limitations pose significant challenges to the widespread use of these potentially life saving treatments. Read more about the hurdles these new treatments still face in our free e-book. Download STAT+ Reads Check out our recent top stories: FDA staff leaned toward rejecting Sarepta gene therapy before top official intervened by Adam Feuerstein and Jason Mast Mindpath seemed like a success story for private equity in mental health. Now, it's a cautionary tale by Olivia Goldhill A bellwether moment: Once a distant dream, gene therapy for Duchenne nears historic decision by Adam Feuerstein and Jason Mast With weight loss drug ads, telehealth companies wade into a regulatory gray area by Mohana Ravindranath READ MORE  Tuesday, May 9, 2023       1 Exchange Place, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us